FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice.

Am J Respir Cell Mol Biol

Faculté de Médecine Xavier Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1152, FHU APOLLO, Labex INFLAMEX, Paris, France.

Published: August 2022

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic possibilities. FGF19 (fibroblast growth factor 19), an endocrine FGF, was recently shown to decrease liver fibrosis. To ask whether FGF19 had antifibrotic properties in the lung and decipher its effects on common features associated with lung fibrogenesis, we assessed, by ELISA, FGF19 concentrations in plasma and BAL fluids obtained from control subjects and patients with IPF. , using an intravenously administered adeno11-associated virus, we overexpressed FGF19 at the fibrotic phase of two experimental models of murine lung fibrosis and assessed its effect on lung morphology, lung collagen content, fibrosis markers, and profibrotic mediator expression at mRNA and protein levels. , we investigated whether FGF19 could modulate the TGF-β-induced differentiation of primary human lung fibroblasts into myofibroblasts and the apoptosis of murine alveolar type II cells. Although FGF19 was not detected in BAL fluid, FGF19 concentration was decreased in the plasma of patients with IPF compared with control subjects. , the overexpression of FGF19 was associated with a marked decrease of lung fibrosis and fibrosis markers, with a decrease of profibrotic mediator expression and lung collagen content. , FGF19 decreased alveolar type 2 epithelial cell apoptosis through the decrease of the proapoptotic BIM protein expression and prevented TGF-β-induced myofibroblast differentiation through the inhibition of JNK phosphorylation. Altogether, these data identify FGF19 as an antifibrotic molecule with potential therapeutic interest in fibrotic lung disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1165/rcmb.2021-0246OCDOI Listing

Publication Analysis

Top Keywords

lung fibrosis
12
fgf19
11
lung
11
idiopathic pulmonary
8
fibrosis
8
pulmonary fibrosis
8
fgf19 antifibrotic
8
control subjects
8
patients ipf
8
lung collagen
8

Similar Publications

Didecyldimethylammonium chloride-induced lung fibrosis may be associated with phospholipidosis.

Toxicol Appl Pharmacol

December 2024

College of Medicine, Graduate School, Kyung Hee University, 02447, Republic of Korea; Division of Cardiology, Department of Internal Medicine, Kyung-Hee University Hospital, Kyung Hee University, 02447, Republic of Korea. Electronic address:

In the current study, we dosed Didecyldimethylammonium chloride (DDAC) in mice by pharyngeal aspiration for 28 days or 90 days (weekly) and tried to elucidate the relationship between lamellar body formation and the lesions. When exposed for 28 days (0, 5, 10, 50, and 100 μg/head), all the mice in the 50 and 100 μg/head groups died since Day 2 after the third dosing (Day 16 after the first dosing). Edema, necrosis of bronchiolar and alveolar epithelium, and fibrinous exudate were observed in the lungs of all the dead mice, and chronic inflammatory lesions were observed in the lung tissues of alive mice.

View Article and Find Full Text PDF

Aim: Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF.

Materials And Methods: Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84).

View Article and Find Full Text PDF

An update on multiple breath washout in children with cystic fibrosis.

Expert Rev Respir Med

December 2024

Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.

Introduction: Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane regulator (CFTR) gene, leading to progressive lung disease and systemic complications. Lung disease remains the primary cause of morbidity and mortality, making early detection of lung function decline crucial. The Lung Clearance Index (LCI), derived from the multiple breath washout (MBW) test, has emerged as a sensitive measure for identifying early airway disease.

View Article and Find Full Text PDF

The interplay between lung galectins and pro-fibrotic markers in post-COVID-19 fibrogenesis: A pilot study.

Life Sci

December 2024

"Aurel Ardelean" Institute of Life Sciences, "Vasile Goldis" Western University of Arad, 310144 Arad, Romania; Department of Histology, Faculty of Medicine, "Vasile Goldis" Western University of Arad, 310144 Arad, Romania. Electronic address:

Aims: COVID-19, caused by the SARS-CoV-2 virus, can lead to serious lung conditions, notably interstitial pulmonary fibrosis.

Main Methods: Our study tracked the progression of fibrosis markers in serial bronchoalveolar lavage (BAL) measurements collected from 16 COVID-19 patients at 1, 3, and 6 months post-infection. Additionally, BAL samples from 10 healthy control subjects were included.

View Article and Find Full Text PDF

Purpose: To develop and validate the patient-reported outcome scale for idiopathic pulmonary fibrosis (IPF-PRO) to provide a reliable and scientific measure for clinical trials on idiopathic pulmonary fibrosis (IPF).

Methods: We analyzed the relevant literature and medical records and conducted interviews and panel discussions to develop the conceptual framework and generate the item pool. We subjected the collected items to removal, mergence, or modification to form the initial scale through a qualitative review by experts and patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!